November 22, 2023 11:01 AM EST

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Syncona scoops up Freeline: British life sciences investor Syncona said Wednesday it agreed to buy gene therapy maker Freeline Therapeutics through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Syn­cona buys gene ther­a­py com­pa­ny; Ory­zon’s €45M fi­nanc­ing agree­ment; In­Dex scraps PhI­II drug

Senior Reporter

Deputy Editor

Sign up to read this article for free.

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug